baricitinib
eli lilly
['baricitinib']
happening today! #prcsg at the #acr22 convergence! baricitinib in juvenile idiopathic arthritis: a phase 3, double-blind, placebo-controlled, withdrawal, efficacy and safety study abstract id: 2210 oral presentation: november 14, 3:15-3:25 pm
The mission of the PRCSG is to conduct high quality clinical trials, of therapeutic agents, in children with rheumatic diseases.